Cytek Biosciences, Inc.
NASDAQ Global SelectTotal Valuation
Cytek Biosciences, Inc. carries a market capitalization of 586.31M, placing it among publicly traded companies globally. Its enterprise value stands at 323.91M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 586.31M |
| Enterprise Value | 323.91M |
Share Statistics
Cytek Biosciences, Inc. currently has 129.14M shares outstanding.
| Shares Outstanding | 129.14M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 2.74, and the price-to-book ratio stands at -4.64.
| PE Ratio | N/A |
| PS Ratio | 2.74 |
| PB Ratio | -4.64 |
| P/TBV Ratio | 1.89 |
| P/FCF Ratio | -317.96 |
| P/OCF Ratio | -76.56 |
Enterprise Valuation
| EV / Sales | 1.59 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | 109.36 |
Financial Position
Cytek Biosciences, Inc. maintains a current ratio of 4.69, meaning it holds 4.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 8.39, indicating elevated leverage, while an interest coverage ratio of -71.84 demonstrates limited ability to service its debt obligations.
| Current Ratio | 4.69 |
| Quick Ratio | 3.94 |
| Debt / Equity | 8.39 |
| Debt / EBITDA | -0.86 |
| Interest Coverage | -71.84 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -15.89 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 2.07 |
Taxes
| Income Tax | 38.06M |
| Effective Tax Rate | N/A |
Stock Price Statistics
Cytek Biosciences, Inc.'s stock has gained approximately 34.7181% over the past 52 weeks. The 50-day moving average sits at 4.18, while the 200-day moving average is 4.56.
| Beta (5Y) | N/A |
| 52-Week Price Change | 34.7181% |
| 50-Day Moving Average | 4.18 |
| 200-Day Moving Average | 4.56 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Cytek Biosciences, Inc. generated 204.17M in revenue and converted that into -74.00M in net income, yielding earnings per share of -0.58. EBITDA reached -31.97M, while operating income came in at -43.87M.
| Revenue | 204.17M |
| Gross Profit | 105.56M |
| Operating Income | -43.87M |
| Pretax Income | -35.95M |
| Net Income | -74.00M |
| EBITDA | -31.97M |
| EBIT | -43.87M |
| Earnings Per Share (EPS) | -0.58 |
Balance Sheet
Cytek Biosciences, Inc. holds 262.23M in cash and equivalents against 27.48M in total debt, resulting in a net debt position of -54.57M. Total book value stands at -120.47M, with working capital of 298.37M providing operational flexibility.
| Cash & Cash Equivalents | 262.23M |
| Total Debt | 27.48M |
| Net Debt | -54.57M |
| Equity (Book Value) | -120.47M |
| Book Value Per Share | -0.94 |
| Working Capital | 298.37M |
Cash Flow
Cytek Biosciences, Inc. produced -7.30M in operating cash flow over the past twelve months. After subtracting -5.54M in capital expenditures, free cash flow totaled -12.84M - equivalent to -0.10 per share.
| Operating Cash Flow | -7.30M |
| Capital Expenditures | -5.54M |
| Free Cash Flow | -12.84M |
| FCF Per Share | -0.10 |
Margins
Cytek Biosciences, Inc. operates with a gross margin of 51.70, reflecting its pricing power and cost economics. The operating margin of -21.49 and net profit margin of -36.25 provide insight into operational efficiency.
| Gross Margin | 51.70 |
| Operating Margin | -21.49 |
| Pretax Margin | -17.61 |
| Profit Margin | -36.25 |
| EBITDA Margin | -15.66 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -0.37 |
| FCF Yield | -0.31 |
Scores
Cytek Biosciences, Inc. posts an Altman Z-Score of 3.36, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 3.36 |